<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huang X</submitter><funding>Program of Clinical Medical Translational Research in Anhui Province</funding><funding>Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei</funding><funding>National Natural Science Foundation of China</funding><funding>Collaborative Innovation Program of Hefei Science Center, CAS</funding><pagination>457</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12896867</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(3)</volume><pubmed_abstract>&lt;b>Background&lt;/b>: Radiation therapy is an important treatment method for non-small-cell lung cancer (NSCLC). However, predicting patient prognosis remains challenging due to considerable interpatient heterogeneity. The TP53 signaling pathway, implicated in tumor radiosensitivity and treatment outcomes, represents a promising predictive biomarker. Accordingly, in this study, we aimed to identify TP53-signaling pathway-related genes and develop a novel prognostic model for risk stratification for NSCLC patients undergoing radiation therapy. &lt;b>Methods&lt;/b>: Publicly available NSCLC transcriptomic datasets were obtained from the GEO and TCGA databases. Utilizing bioinformatics approaches, we identified differentially expressed genes (DEGs) associated with the TP53 signaling pathway. Feature s</pubmed_abstract><journal>Cancers</journal><pubmed_title>A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer.</pubmed_title><pmcid>PMC12896867</pmcid><funding_grant_id>2022HSC-CIP015</funding_grant_id><funding_grant_id>202304295107020092</funding_grant_id><funding_grant_id>2021YL007</funding_grant_id><funding_grant_id>81872438</funding_grant_id><pubmed_authors>Fang Y</pubmed_authors><pubmed_authors>Jiao L</pubmed_authors><pubmed_authors>Qi J</pubmed_authors><pubmed_authors>Hu Z</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Nie J</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Cheng X</pubmed_authors><pubmed_authors>Hong B</pubmed_authors></additional><is_claimable>false</is_claimable><name>A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer.</name><description>&lt;b>Background&lt;/b>: Radiation therapy is an important treatment method for non-small-cell lung cancer (NSCLC). However, predicting patient prognosis remains challenging due to considerable interpatient heterogeneity. The TP53 signaling pathway, implicated in tumor radiosensitivity and treatment outcomes, represents a promising predictive biomarker. Accordingly, in this study, we aimed to identify TP53-signaling pathway-related genes and develop a novel prognostic model for risk stratification for NSCLC patients undergoing radiation therapy. &lt;b>Methods&lt;/b>: Publicly available NSCLC transcriptomic datasets were obtained from the GEO and TCGA databases. Utilizing bioinformatics approaches, we identified differentially expressed genes (DEGs) associated with the TP53 signaling pathway. Feature s</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-09T13:10:35.223Z</modification><creation>2026-07-09T13:09:01.009Z</creation></dates><accession>S-EPMC12896867</accession><cross_references><pubmed>41681932</pubmed><doi>10.3390/cancers18030457</doi></cross_references></HashMap>